

BBIBP-CorV

S

Stevens-Johnson-syndrome: case report

A 32-year-old man developed Stevens-Johnson syndrome following the vaccination with BBIBP-CorV vaccine for COVID-19.

The man presented with blistering rash on his hands, erythematous plaque with peeling dermis on his chest, back, skull, face and neck. Six hours after the second dose of BBIBP-CorV [Sinopharm COVID-19 vaccine; *dosage and route not stated*], he developed the aforementioned symptoms. The ophthalmologic examination showed visual acuity 20/20, palpebral oedema and erythema, BUT <10s, grade III bulbar conjunctival hyperaemia and superficial punctate keratitis in both eyes. He also had signs of fibrosing conjunctivitis, two symblepharon stage IIIA and IIID occupying respectively 0–25% and 75–100% of the length of the lower lid in the left eye. Based on these examinations, a diagnosis of BBIBP-CorV vaccine-induced Stevens-Johnson syndrome was made.

The man's treated with tobramycin, ascorbic acid, eye wash, unspecified corticosteroids, retinol, doxycycline and preservative-free eye drops. Thirty days later, a regression of palpebral erythema and oedema, conjunctival hyperaemia and superficial punctate keratitis were noted.

Boualila L, et al. Sinopharm COVID-19 vaccine-induced Stevens-Johnson syndrome. *Journal Francais d'Ophtalmologie* 45: e179-e182, No. 4, Apr 2022. Available from:

URL: <http://doi.org/10.1016/j.jfo.2021.12.005>

803662538